CAR T cell therapy has been a success in hematological malignancies. The FDA and EMA approved CART19 (Kymriah & Yescarta) to treat pediatric relapsed or refractory acute lymphoblastic leukemia (ALL) and for adult relapsed or refractory large B cell lymphoma in 2017 & 2018 respectively.
For solid tumors, CAR T cell therapy has shown promising results in early phase of clinical trials. Results of most of the trials are awaited. Here is the glimpse for recent pipeline update for all types of CART therapies in development for solid tumors:
| Type of CART | Solid Tumor Type | Clinical Phase | NCT | |
|---|---|---|---|---|
| 1 | CD147-CART | Recurrent Glioblastoma | Early Phase 1 | NCT04045847 |
| 2 | CD147-CART | Advanced Hepatocellular Carcinoma | Phase I | NCT03993743 |
| 3 | LeY CAR T cells | Advanced Cancer (Not specified) | Phase I | NCT03851146 |
| 4 | CAR-T cells targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, or CD80/86 | Lung Cancer | Phase I | NCT03198052 |
| 5 | MUC-1 CART cell immunotherapy | Intrahepatic Cholangiocarcinoma | Phase I/II | NCT03633773 |
| 6 | CAR-T cells targeting EpCAM | Neoplasm, Stomach|Metastases, Neoplasm|Neoplasm Seeding | Phase I | NCT03563326 |
| 7 | CAR T Cells Targeting EpCAM | Colon Cancer|Esophageal Carcinoma|Pancreatic Cancer|Prostate Cancer|Gastric Cancer|Hepatic Carcinoma | Phase I/II | NCT03013712 |
| 8 | Sarcoma-specific CAR-T cells (CD133, GD2, Muc1, CD117 or other marker positive sarcoma) | Sarcoma|Osteoid Sarcoma|Ewing Sarcoma | Phase I/II | NCT03356782 |
| 9 | Anti-CTLA-4/PD-1 expressing MUC1-CAR-T | Advanced Solid Tumor (Not specified) | Phase I/II | NCT03179007 |
| 10 | PD-L1 CAR-T cells | Advanced Lung Cancer | Phase I | NCT03330834 |
| 11 | GD2, PSMA, Muc1 or Mesothelin positive | Cervical Cancer | Phase I/II | NCT03356795 |
| 12 | GPC3 targeting CAR-T cells | Hepatocellular Carcinoma|Squamous Cell Lung Cancer | Phase I | NCT03198546 |
| 13 | Anti-HER2 CAR-T | Breast Cancer|Ovarian Cancer|Lung Cancer|Gastric Cancer|Colorectal Cancer|Glioma|Pancreatic Cancer | Phase I/II | NCT02713984 |
| 14 | 1RG-CART | Relapsed or Refractory Neuroblastoma | Phase I | NCT02761915 |
| 15 | c-Met/PD-L1 CAR-T cell injection | Primary Hepatocellular Carcinoma | Early Phase 1 | NCT03672305 |
| 16 | EGFR806-specific chimeric antigen receptor (CAR) T cell | Central Nervous System Tumor, Pediatric|Glioma|Ependymoma|Medulloblastoma|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma | Phase I | NCT03638167 |
| 17 | anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Advanced Solid Tumor (Not specified) | Phase I/II | NCT03182816 |
| 18 | HER2-specific chimeric antigen receptor (CAR) T cell | Central Nervous System Tumor, Pediatric|Glioma|Ependymoma|Medulloblastoma|Germ Cell Tumor|Atypical Teratoid/Rhabdoid Tumor|Primitive Neuroectodermal Tumor|Choroid Plexus Carcinoma|Pineoblastoma | Phase I | NCT03500991 |
| 19 | CAR-T therapy for Nectin4/FAP | Nectin4-positive Advanced Malignant Solid Tumor | Phase I | NCT03932565 |
| 20 | CAR-T cells recognizing EpCAM | Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M)|Breast Cancer Recurrent | Phase I | NCT02915445 |
| 21 | GD2-CART01 | Neuroblastoma|Neuroblastoma Recurrent | Phase I/II | NCT03373097 |
| 22 | C7R-GD2.CART cells | Relapsed Neuroblastoma|Refractory Neuroblastoma | Phase I | NCT03635632 |
| 23 | CART-EGFR | Advanced EGFR-positive Solid Tumors (lung cancer, colorectal cancer, ovary cancer, cholangiocarcinoma, pancreatic cancer, renal carcinoma and other relapsed/metastatic tumors) | Phase I/II | NCT01869166 |
| 24 | anti-EGFR CAR T | Advanced Glioma | Phase I | NCT02331693 |
| 25 | EGFR806 CAR T Cell | Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma | Phase I | NCT03618381 |
| 26 | Anti-CEA-CAR T | Lung Cancer|Colorectal Cancer|Gastric Cancer|Breast Cancer|Pancreatic Cancer | Phase I | NCT02349724 |
| 27 | Mesothelin-directed CAR-T cells | Solid Tumor, Adult (Pancreatic cancer, cholangiocarcinoma cancer and ovarian cancer) | Phase I | NCT03747965 |
| 28 | anti-MESO CAR-T cells | Ovarian Cancer | Phase I/II | NCT03916679 |
| 29 | Anti-GD2 CART | Neuroblastoma | Phase II | NCT02765243 |
| 30 | EGFRvIII CAR T cells | Glioblastoma|Gliosarcoma | Phase I | NCT02664363 |
| 31 | CART-HER-2 | Advanced HER-2 Positive Solid Tumors|Chemotherapy Refactory|HER-2 Antibody Inhibitor Therapy Refactory ((breast cancer, gastric cancer, hepatic carcinoma, endometrial cancer and ovary cancer) | Phase I/II | NCT01935843 |
| 32 | PSMA-TGF?RDN CAR T cells | Prostate Cancer | Phase I | NCT03089203 |
| 33 | HER2-CAR T Cells | HER2/Neu Positive|Malignant Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Leptomeninges | Phase I | NCT03696030 |
| 34 | CARTmeso CART19 | Pancreatic Cancer | Early Phase 1 | NCT03497819 |
| 35 | CART-EGFRvIII T cells | Glioblastoma | Phase I | NCT03726515 |
| 36 | CTLA-4/PD-1 antibodies expressing mesoCAR-T | Advanced Solid Tumor (Not specified) | Phase I/II | NCT03182803 |
| 37 | LMP1-CAR-T cells | Nasopharyngeal Neoplasms | Phase I/II | NCT02980315 |
| 38 | anti-mesothelin CAR-T cells | Solid Tumor, Adult (Not specified) | Phase I | NCT03545815 |
| 39 | Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs | Hepatocellular Carcinoma | Phase I/II | NCT03084380 |
| 40 | Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes | Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8|PSCA Positive | Phase I | NCT03873805 |
| 41 | anti-CD133-CAR vector-transduced T cells | Liver Cancer|Pancreatic Cancer|Brain Tumor|Breast Cancer|Ovarian Tumor|Colorectal Cancer | Phase I/II | NCT02541370 |
| 42 | Corticosteroids & tanCART19/20 | Neuromyelitis Optica Spectrum Disorder | Phase I | NCT03605238 |
| 43 | huCART-meso cells | Pancreatic Cancer | Phase I | NCT03323944 |
| 44 | 4SCAR-PSMA-T Cell | Bladder Cancer|Urothelial Carcinoma Bladder | Phase I/II | NCT03185468 |
| 45 | anti-meso-CAR vector transduced T cells | Malignant Mesothelioma|Pancreatic Cancer|Ovarian Tumor|Triple Negative Breast Cancer|Endometrial Cancer|Other Mesothelin Positive Tumors | Phase I | NCT02580747 |
| 46 | Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells) | Neuroblastoma|Ganglioneuroblastoma | Phase I | NCT02311621 |
| 47 | Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) | Malignant Melanoma|Breast Cancer | Early Phase 1 | NCT03060356 |
| 48 | CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 | Neuroblastoma | Phase I | NCT03721068 |
| 49 | GLYCAR T cells | Hepatocellular Carcinoma | Phase I | NCT02905188 |
| 50 | 4SCAR-GD2 | Solid Tumor (Not specified) | Phase I/II | NCT02992210 |
| 51 | PD-1 antibody expressing mesoCAR-T cells | Advanced Solid Tumor (Malignant mesothelioma, pancreatic cancer, bile duct cancer, ovarian cancer, lung cancer, gastric cancer) | Phase I/II | NCT03615313 |
| 52 | IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells | Recurrent Glioblastoma|Refractory Glioblastoma | Phase I | NCT04003649 |
| 53 | EGFRvIII-CARs | Recurrent Glioblastoma|Recurrent Gliosarcoma | Phase I | NCT03283631 |
| 54 | GAP T cells | Liver Cancer Pediatric | Phase I | NCT02932956 |
| 55 | huCART-meso cells | Lung Adenocarcinoma|Ovarian Cancer|Peritoneal Carcinoma|Fallopian Tube Cancer|Mesotheliomas Pleural|Mesothelioma Peritoneum | Phase I | NCT03054298 |
| 56 | iCasp9M28z T cell infusions | Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer | Phase I | NCT02414269 |
| 57 | ROR1 CAR-specific Autologous T-Lymphocytes | Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Non-Small Cell Lung Cancer AJCC v7|Triple-Negative Breast Carcinoma | Phase I | NCT02706392 |
| 58 | HER2-specific T cells | Brain Tumor, Recurrent|Brain Tumor, Refractory | Phase I | NCT02442297 |
| 59 | EBV-TCR-T (YT-E001) cells | Nasopharyngeal Carcinoma | Phase II | NCT03648697 |
| 60 | GD2 T cells | Osteosarcoma|Neuroblastoma | Phase I | NCT01953900 |
| 61 | CAR-CLDN18.2 T-Cells | Advanced Solid Tumor (Advanced gastric cancer, esophagogastric junction cancer, and pancreatic cancer) | Phase I | NCT03874897 |
| 62 | OC-IgT cells | Ovarian Cancer | Phase I/II | NCT03184753 |
| 63 | CAdVEC | Bladder Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Salivary Gland|Lung Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer|Pancreatic Adenocarcinoma | Phase I | NCT03740256 |
| 64 | Antigen-specific IgT cells | Glioblastoma Multiforme of Brain|Glioblastoma Multiforme | Phase I | NCT03170141 |
| 65 | Autologous HER2-specific T cells | Sarcoma | Phase I | NCT00902044 |
| 66 | Lung cancer-specific T cells (MAGE-A1, MAGE-A4, MucI, GD2, and mesothelin,) | Lung Cancer | Phase I/II | NCT03356808 |
| 67 | iC9-GD2 T Cells - frozen | Neuroblastoma | Phase I | NCT01822652 |
| 68 | CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes | Glioblastoma|HER2/Neu Positive|Malignant Glioma|Recurrent Glioma|Refractory Glioma|WHO Grade III Glioma | Phase I | NCT03389230 |
For more information for CART cell therapy pipeline, please contact at [email protected]
Leave a Reply